Urine-Based Test Improves Detection of Prostate Cancer
By LabMedica International staff writers Posted on 01 Jun 2015 |
Image: Histopathology of a prostate biopsy showing normal prostatic glands and glands of prostate cancer prostate adenocarcinoma in right upper aspect of image (Photo courtesy of Nephron).
A new urine-based test improved prostate cancer detection, including detecting more aggressive forms of prostate cancer, compared to traditional models based on prostate serum antigen, or PSA, levels.
The test reports individual risk estimates for prostate cancer (PCa) and high grade cancer and each patient's personal threshold for choosing to undergo biopsy may vary, so there is no single cutoff for a "positive" result.
A team of scientists led by those at the University of Michigan Medical School (Ann Arbor, MI, USA) developed the test, which they called Mi-Prostate Score, or MiPS. It combines PSA with two markers for prostate cancer, transmembrane protease, serine 2: V-ets avian erythroblastosis virus E26 oncogene homolog (T2:ERG) and prostate cancer antigen 3 (PCA3), both of which can be detected in a urine sample.
The team studied a total of 1,977 men who were undergoing prostate biopsy because of elevated PSA levels. Using urine samples, the team conducted MiPS testing and compared results to various combinations of PSA, PCA3, T2:ERG and other PSA-based risk calculators. They assessed how well the individual biomarkers and combinations of biomarkers predicted the likelihood of cancer and the likelihood of high-risk cancer, the aggressive type that needs immediate treatment.
Among informative validation cohort samples from 1,225 men, 80% from patients presenting for initial biopsy, models incorporating T2: ERG had significantly greater area under the curve (AUC) than PSA or multivariate Prostate Cancer Prevention Trial risk calculator version (PCPTrc) for predicting or high-grade PCa (Gleason score greater than 6) on biopsy. MiPS models incorporating T2:ERG score had significantly greater AUC than models incorporating only PCA3 plus PSA (or PCPTrc or high-grade cancer PCPTrc [PCPThg]).
Scott A. Tomlins, MD, PhD, assistant professor of pathology and urology and lead author of the study said, “Around 50% of men who undergo a prostate biopsy will not have cancer. We need better ways to manage elevated PSA and determine who really needs to have a biopsy. MiPS gives men and their doctors better information to help make those decisions.” The study was published on May 16, 2015, in the journal European Urology.
Related Links:
University of Michigan Medical School
The test reports individual risk estimates for prostate cancer (PCa) and high grade cancer and each patient's personal threshold for choosing to undergo biopsy may vary, so there is no single cutoff for a "positive" result.
A team of scientists led by those at the University of Michigan Medical School (Ann Arbor, MI, USA) developed the test, which they called Mi-Prostate Score, or MiPS. It combines PSA with two markers for prostate cancer, transmembrane protease, serine 2: V-ets avian erythroblastosis virus E26 oncogene homolog (T2:ERG) and prostate cancer antigen 3 (PCA3), both of which can be detected in a urine sample.
The team studied a total of 1,977 men who were undergoing prostate biopsy because of elevated PSA levels. Using urine samples, the team conducted MiPS testing and compared results to various combinations of PSA, PCA3, T2:ERG and other PSA-based risk calculators. They assessed how well the individual biomarkers and combinations of biomarkers predicted the likelihood of cancer and the likelihood of high-risk cancer, the aggressive type that needs immediate treatment.
Among informative validation cohort samples from 1,225 men, 80% from patients presenting for initial biopsy, models incorporating T2: ERG had significantly greater area under the curve (AUC) than PSA or multivariate Prostate Cancer Prevention Trial risk calculator version (PCPTrc) for predicting or high-grade PCa (Gleason score greater than 6) on biopsy. MiPS models incorporating T2:ERG score had significantly greater AUC than models incorporating only PCA3 plus PSA (or PCPTrc or high-grade cancer PCPTrc [PCPThg]).
Scott A. Tomlins, MD, PhD, assistant professor of pathology and urology and lead author of the study said, “Around 50% of men who undergo a prostate biopsy will not have cancer. We need better ways to manage elevated PSA and determine who really needs to have a biopsy. MiPS gives men and their doctors better information to help make those decisions.” The study was published on May 16, 2015, in the journal European Urology.
Related Links:
University of Michigan Medical School
Latest Molecular Diagnostics News
- Blood Proteins Could Warn of Cancer Seven Years before Diagnosis
- New DNA Origami Technique to Advance Disease Diagnosis
- Ultrasound-Aided Blood Testing Detects Cancer Biomarkers from Cells
- New Respiratory Syndromic Testing Panel Provides Fast and Accurate Results
- New Synthetic Biomarker Technology Differentiates Between Prior Zika and Dengue Infections
- Novel Biomarkers to Improve Diagnosis of Renal Cell Carcinoma Subtypes
- RNA-Powered Molecular Test to Help Combat Early-Age Onset Colorectal Cancer
- Advanced Blood Test to Spot Alzheimer's Before Progression to Dementia
- Multi-Omic Noninvasive Urine-Based DNA Test to Improve Bladder Cancer Detection
- First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans